GET DAILY SIGNALSQ32 Bio (QTTB) Climbs +8.7% Over the Trailing 30 Days
Key Takeaways
- Q32 Bio (QTTB) shares have risen roughly 8.7% over the trailing 30 days, from about $8.01 to $8.71, although the stock still trades well below its mid-2026 peak reached after the July SIGNAL-AA data release.
- The company is a clinical-stage biotechnology firm advancing bempikibart, an anti-IL-7Rα antibody, for severe or very severe alopecia areata.
- Positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial, followed by a $200 million public offering, were the dominant catalysts for 2026.
- Third-quarter 2026 results, reported in early November, showed a narrower-than-expected per-share loss and cash of roughly $289.6 million, which management says funds operations through Phase 3 topline results.
- Analyst consensus is a Strong Buy, with an average price target near $39–$40, well above recent trading levels.
- The company is preparing to begin a registration-directed program in the first half of 2027, subject to regulatory discussions.
Recent Price Action and Market Context
Q32 Bio closed at $8.71 on November 13, 2026, extending a modest recovery that has carried the stock roughly 8.7% higher over the trailing 30 days from the $8.01 close recorded around October 14. The move has been choppy rather than linear: shares pulled back sharply through late September before stabilizing in the low-$8 range and gradually firming into November.
The stock's recent behavior reflects the aftereffects of a volatile 2026. Q32 Bio shares surged in July after the company reported positive topline data for bempikibart, only to give back a large portion of those gains as investors weighed the dilutive impact of a subsequent $200 million equity raise. With a market capitalization in the low hundreds of millions of dollars, QTTB sits firmly in the clinical-stage, small-cap biotechnology category, where sentiment is driven largely by data readouts, regulatory milestones, and financing activity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Background and Pipeline Focus
Q32 Bio is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on restoring healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases. The company's science targets potent regulators of the adaptive immune system, specifically the IL-7 and TSLP signaling pathways, which have been genetically and biologically implicated in multiple T cell-mediated conditions.
Its lead program, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function. Roughly 700,000 people in the United States live with alopecia areata, a disease with limited treatment options, and Q32 Bio is advancing bempikibart through an ongoing Phase 2 program with the goal of moving into a registration-directed trial. The company also has a half-life-extended follow-on candidate, ADX-914-XL, in preclinical development. Q32 Bio began trading on the Nasdaq under the symbol QTTB in March 2024 following its merger with Homology Medicines.
Key Catalysts and Recent Developments
Several verified developments have shaped Q32 Bio's trajectory. In July 2026, the company reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in patients with severe or very severe alopecia areata, showing meaningful hair regrowth, early signs of durability in the off-drug period, and a generally well-tolerated safety profile. The data prompted a sharp rally and a wave of analyst action, including an upgrade to Overweight at Wells Fargo with a $66 price target and a reiterated Outperform rating at Oppenheimer.
Soon after, Q32 Bio completed a $200 million public offering of common stock and pre-funded warrants, strengthening its balance sheet but diluting existing shareholders and contributing to the stock's pullback. In September, the company appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer, signaling its transition toward late-stage development. In early November, Q32 Bio reported third-quarter 2026 results with a GAAP loss per share of $0.26, narrower than expected, and cash of about $289.6 million as of September 30, 2026. The company also presented additional SIGNAL-AA data at the EADV Congress and participated in the Jefferies Global Healthcare Conference.
2027 Outlook and Key Areas to Monitor
The central catalyst for Q32 Bio is the planned initiation of a registration-directed program for bempikibart in severe or very severe alopecia areata, which the company expects to begin in the first half of 2027, pending regulatory discussions in the second half of 2026. Long-term follow-up data from the SIGNAL-AA Part B open-label extension, anticipated in the second half of 2027, will help inform the chronic maintenance dosing regimen and could shape the commercial profile of the therapy.
Investors should also monitor progress on ADX-914-XL, cash utilization against the company's stated runway to Phase 3 topline results, and any further equity financing that could dilute shareholders. Competitive dynamics in alopecia areata, broader risk appetite for clinical-stage biotech, and evolving analyst price targets will remain important context. As with all clinical-stage biotechnology companies, trial outcomes and regulatory decisions carry inherent uncertainty. From what I see, this is important because it sets the stage for potential value inflection points in the coming year.
Exploring AI Tools for Trading Insights
In my view, one resource that has proven useful for tracking automated strategies around names like QTTB is Tickeron’s AI Trading Bots. The platform offers a range of data-driven approaches that complement traditional fundamental research, allowing users to review how systematic signals align with clinical and market developments. I’m watching this closely as a way to add another layer of perspective to the analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
QTTB's RSI Indicator ascends from oversold territory
The RSI Oscillator for QTTB moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 28 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for QTTB just turned positive on October 08, 2026. Looking at past instances where QTTB's MACD turned positive, the stock continued to rise in 33 of 36 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 165 of 188 cases where QTTB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 49 cases where QTTB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTTB as a result. In 79 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 50-day moving average for QTTB moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
QTTB broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.600) is normal, around the industry mean (3.498). P/E Ratio (2.946) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement